Background:Esophageal cancer presents as a locally advanced disease in majority of the patients. The purpose of this study was to report our experience of the outcomes of definitive chemoradiotherapy in locally advanced unresectable esophageal cancers. Material & Methods:Patients diagnosed with carcinoma esophagus treated at our center with curative intent with chemoradiotherapy from March 2017 to June 2022 were included in this retrospective study. Pretreatment evaluation and staging was done.The status of the patient was noted at the last follow up. The patients were contacted and their status and survival was updated in June 2023. The statistical analysis was done by SPSS version 25 for demographic details. Control rates and survival were calculated using Kaplan-Meier method. Results:60 Gy , 50.4 Gy and 35Gy/15# followed by 25Gy /10# were received by 63.6% , 18.2%and 18.2% patients respectively. Only 59.1% patients could receive concomitant chemotherapy with 3 mean no. of cycles. At the median follow up period of 11 months, local control rate is 95.5% , nodal control rate 97.7% , distant control rate was 85 % and overall survival is 91.2%. 52.3% patients had no disease on last follow up. Conclusion:The study concluded thatradiation is the best modality of treatment in unresectable esophageal cancer patients, especially when combined with chemotherapy.